<?xml version="1.0" encoding="UTF-8"?>
<!-- Generated on Sun, 22 Nov 2026 12:03:28 -0500 -->
<rss version="2.0" xmlns:content="http://purl.org/rss/1.0/modules/content/">
  <channel>    <title>CytoDyn Inc. (CYDY) News</title>
    <link>https:///rss</link>
    <description>The latest news released by CytoDyn Inc. (CYDY)</description>
    <language>en-us</language>
    <generator>Equisolve Investor Relations Suite</generator>
    <item>
      <title>CytoDyn Appoints Lauren Wilcoxen, Ph.D., as Chief Operating Officer and Head of Regulatory Affairs</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/675/cytodyn-appoints-lauren-wilcoxen-ph-d-as-chief-operating</link>
      <pubDate>Tue, 17 Nov 2026 08:30:00 -0500</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/675/cytodyn-appoints-lauren-wilcoxen-ph-d-as-chief-operating</guid>
<content:encoded><![CDATA[

<p align="justify" style="text-align:justify;">VANCOUVER, Washington, Nov.  17, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY)</strong>&nbsp;("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and triple-negative breast cancer (TNBC), today announced Lauren Wilcoxen, Ph.D., as its new Chief Operating Officer and Head of Regulatory Affairs, effective November 20, 2026.</p>  <p align="justify" style="text-align:justify;">Dr. Wilcoxen brings extensive experience in regulatory affairs, clinical development and biotechnology operations, including a track record of advancing oncology programs through key regulatory milestones. Most recently, she served as Senior Vice President of Regulatory Affairs at Xilio Therapeutics, Inc. (NASDAQ: XLO), a publicly traded clinical-stage biotechnology company. From May 2022 to October 2025, Dr. Wilcoxen helped lead a team that secured FDA approval of a novel checkpoint inhibitor for skin cancer while serving as Senior Vice President, Product Development and Regulatory Affairs of Checkpoint Therapeutics, Inc. (formerly, NASDAQ: CKPT), a publicly traded clinical-stage biotechnology company, until its acquisition by Sun Pharmaceutical Industries, Inc. in 2025. Over the past several years, she has also advised various public and private biotechnology and pharmaceutical companies on regulatory strategy, clinical development and operational execution, with a focus on navigating complex oncology development programs and coordinating cross-functional teams.</p>  <p align="justify" style="text-align:justify;">“Lauren's appointment comes at an important time for CytoDyn as we continue to advance our oncology development strategy and build on emerging findings from our CLOVER study,” said Robert E. Hoffman, Chief Executive Officer of CytoDyn. “Her extensive regulatory expertise, recent success working with the FDA's Division of Oncology, and firsthand knowledge of our clinical programs make her exceptionally well suited to help guide CLOVER through the completion of Phase 2 and shape our regulatory strategy for the next stages of leronlimab's development. We are pleased to welcome her to our executive leadership team.”</p>  <p align="justify" style="text-align:justify;">Dr. Wilcoxen has served as a consultant to CytoDyn over the past year, advising on key clinical decisions and gaining firsthand knowledge of the Company's clinical programs, including its Phase 2 CLOVER study evaluating leronlimab in metastatic colorectal cancer.</p>  <p align="justify" style="text-align:justify;">“Having worked closely with CytoDyn over the past year, I have developed a strong understanding of leronlimab's scientific rationale, the CLOVER study, and the opportunities ahead for the Company's oncology programs,” said Dr. Wilcoxen. “I am encouraged by the emerging clinical findings and look forward to working with the team to translate these insights into a clear, rigorous regulatory and clinical development strategy. Our priority will be to work closely with the FDA to define a clear regulatory strategy that supports leronlimab’s continued clinical development.”</p>  <p align="justify" style="text-align:justify;">Dr. Wilcoxen currently serves on the board of directors of two cancer nonprofits, the American Cancer Society and Caring Community Foundation, and was named one of the Top 50 Women Leaders in Healthcare by Women We Admire in January 2025. She also holds a Regulatory Affairs Certification (RAC) from the Regulatory Affairs Professionals Society, a Ph.D. in microbiology and immunology from The University of North Carolina at Chapel Hill, and a B.S. in biology from Mount Saint Mary’s University.</p>  <p align="justify" style="text-align:justify;"><strong>About CytoDyn</strong></p>  <p align="justify" style="text-align:justify;">CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p align="justify" style="text-align:justify;">For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=0W6hNYFzhDIo3nPDYoLan3bGGMCMQlsxoI4Vj4zEJY1mFENkRiapXytbhF-I8IAvBf1IdbNT0FoH95ZVA_6k1G2OTbIC8rBoL2Uog69FBpVAyQxydhbNB1XUV1YdlYzJOQKQY-AvytD1RcVvkI5HHEjXb8zscM_6PTRp6aJAeO_tYimi_MDh9QV4U2pgjQVB3zZRrAKZqmQ_oklD__ckepMDFxpugSunAiiIcYq44xtUBW0_3-TnvqRT41J7C49gbsggdcv_OE1jgpaZT60XiQ==" rel="nofollow" target="_blank">www.cytodyn.com</a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=1cnP5kqjI23ISlSPZh9bSs00McpE8ZHecvP9qVb1ABZG55QERC6Ua3Ty33iuUvH5c7ccR8XYqIBXUdO5b2zb1peGY7DcAG0YDJknwU21JG-tanYrcvPZcb6zv0BIbxMaAh5RaKDEVcak5NGQO6v8xTvVgIrb5xr_5WgaaIvY-VKIkTIrSoc28GXYE0bAWT4AEVBy_B9owVdO9NWkkQol1iKe46pWGYNNKOXG8oOm4fKH6OLzC8OtAHtvngk0oXGe" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p align="justify" style="text-align:justify;"><strong>Note Regarding Forward-Looking Statements</strong></p>  <p align="justify" style="text-align:justify;">This news release may contain forward-looking statements relating to, among other things, mechanism of action, clinical development programs, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p><strong>Corporate Contact</strong><br>CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=8xi-a9DFTVJZJSOtnjFjBGNP0p_N-eIIdjbEXEExj0_wZXQJuy2kB3vXLN5cb0tFOgCidA-dFGR6o_AKCe2X3w==" rel="nofollow" target="_blank">ir@cytodyn.com</a></p>  <p><strong>Media Contacts</strong><br>David Schull or Ignacio Guerrero-Ros, Ph.D. <br>Russo Partners, LLC<br><a href="https://www.globenewswire.com/Tracker?data=7DLY2Wv6w2HwtmL-pAC3Yt0d8RHIT5EEiAtlESbMsqHAjtXCcyUJYc9HSBJmJAz002kjFLFQrEYoBrKYhPV5gaQ0_bW5UnHL1Po3IpjB6JSvh3Pa4_ye1HkykEVrQ2I9yQpIt_2hDVn88sm-Cgcpr4nfLmtXEG4CyboJOOhHavQyUqWPgzya8Qzhs2_Y9eZBtb1QSG3h1Oxp0pjG2hdo036qiLKeaWTE59qqcpucMLvemmNHY8AIsqps-SpASEHpMGavcY-I1dLxITCWqFLmvPEzmRoD2Y5wGzkdOeWInsSLNCRBZbZ-Omko4RMZ9pXc" rel="nofollow" target="_blank">CytoDyn@russopartnersllc.com</a></p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
    <item>
      <title>CytoDyn Announces $5 Million Private Investment to Advance Leronlimab in Colorectal Cancer and Other Solid Tumors</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/674/cytodyn-announces-5-million-private-investment-to-advance</link>
      <pubDate>Thu, 12 Nov 2026 08:30:00 -0500</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/674/cytodyn-announces-5-million-private-investment-to-advance</guid>
<content:encoded><![CDATA[

<p align="justify" style="text-align:justify;">VANCOUVER, Washington, Nov.  12, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY) </strong>("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and triple-negative breast cancer (TNBC), today announced that a private investor has made an additional $5 million investment into the Company in support of its clinical development of leronlimab.</p>  <p align="justify" style="text-align:justify;">The investor, who wishes to remain anonymous at this time, has previously invested in the Company and has a longstanding interest in advancing innovative cancer therapies and improving patient access to promising treatment approaches. The investment was completed at a purchase price of $0.24 per common share, with no accompanying warrants, resulting in total proceeds of $5 million. The proceeds will support further development of the Company's colorectal cancer program, building on emerging findings from its CLOVER study, while also furthering the exploration of leronlimab in earlier lines of treatment and other oncology indications, including TNBC, pancreatic cancer and glioblastoma.</p>  <p align="justify" style="text-align:justify;">“We are grateful for this investor’s continued confidence in leronlimab and commitment to supporting the development of new treatment options for patients with cancer,” said Robert E. Hoffman, Chief Executive Officer of CytoDyn. “We believe this investment reflects support for CytoDyn’s recent data, as well as the emerging scientific and clinical evidence supporting leronlimab's therapeutic potential across multiple solid-tumor indications. The investment comes at an important time as we continue to build on emerging clinical findings and advance the development of leronlimab across multiple solid tumors. This support will help us advance our clinical and translational research efforts as we continue to generate the evidence needed to inform future regulatory pathways.”</p>  <p align="justify" style="text-align:justify;"><strong>About CytoDyn</strong></p>  <p align="justify" style="text-align:justify;">CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p>For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=MXcwd_MtKhWPMmC71cZMEbhxhoD3pbgp29fCOi2insb7FpzI0wJINSnz9a2DzVPsck0Cai-sDdNXYI-gFcFX63CndKwKalwTFcpPfgq5k60=" rel="nofollow" target="_blank">www.cytodyn.com</a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=6JxVSs3tPYcmzTGJ4kkIaD7GjSRA3NXwXZMKOrcevTtz-epMr3GmlFrP00ZDk1lgeAREH-q-CkJgQYIuvhHbAtJYOQpzhNgHkcihzzPtOFg=" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Note Regarding Forward-Looking Statements</strong></p>  <p>This news release may contain forward-looking statements relating to, among other things, mechanism of action, clinical development programs, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p><strong>Corporate Contact</strong></p>  <p>CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=3mJR_NcmxnGVLczZ_RjF39jf4E2raWxZn9WGCXQc6BiB39AFeH6K0SyAvuScYZKj_kKUU_XB8e6AUbe02drLAw==" rel="nofollow" target="_blank">ir@cytodyn.com</a></p>  <p><strong>Media Contacts</strong></p>  <p>David Schull or Ignacio Guerrero-Ros, Ph.D. <br>Russo Partners, LLC<br><a href="https://www.globenewswire.com/Tracker?data=6sj4OYCBCGMqti7i8pfz_cWw2GrfplMojFoG21X2d6Os_ZBK8cg1AsdimR7T08dSI1tsNmHq4w1oWfZ0fIjQ998HpbmiNEXxYq-ZnBq7pPwATgxjI_xXbXhWM4isi_Az" rel="nofollow" target="_blank">CytoDyn@russopartnersllc.com</a></p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
    <item>
      <title>CytoDyn and QLHC Advance Leronlimab into Two New PRE-I-SPY Studies in Metastatic Triple-Negative Breast Cancer</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/673/cytodyn-and-qlhc-advance-leronlimab-into-two-new-pre-i-spy</link>
      <pubDate>Tue, 10 Nov 2026 08:30:00 -0500</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/673/cytodyn-and-qlhc-advance-leronlimab-into-two-new-pre-i-spy</guid>
<content:encoded><![CDATA[

<p align="justify" style="text-align:justify;">VANCOUVER, Washington, Nov.  10, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY)</strong>&nbsp;("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (CRC) and metastatic triple-negative breast cancer (mTNBC), today announced that leronlimab will be evaluated in two new mTNBC regimens within the Quantum Leap Healthcare Collaborative’s (QLHC) PRE-I-SPY Phase 1-1b platform study, with enrollment expected to begin shortly.</p>  <p align="justify" style="text-align:justify;">The two studies will evaluate leronlimab in distinct immunotherapy-based combinations, each incorporating a PD-1 inhibitor. PRE5 will evaluate leronlimab alongside Merck's pembrolizumab and the antibody-drug conjugate sacituzumab, while PRE7 will evaluate leronlimab in combination with Akeso's penpulimab and the standard chemotherapy agents gemcitabine and carboplatin. Both studies are designed to assess safety and tolerability in earlier-line metastatic treatment settings while exploring preliminary signals of clinical activity.</p>  <p align="justify" style="text-align:justify;">“These studies represent an important opportunity to further investigate the potential of CCR5 inhibition as part of combination treatment strategies for patients with metastatic triple-negative breast cancer,” said Jacob Lalezari, M.D., Head of Research and Translational Sciences at CytoDyn. “By evaluating leronlimab alongside different immunotherapy-based regimens and incorporating exploratory biomarker analyses, we hope to gain a better understanding of its potential role in modulating the tumor microenvironment and informing future treatment approaches for patients with this aggressive disease.”</p>  <p align="justify" style="text-align:justify;">mTNBC is an aggressive form of breast cancer characterized by the absence of estrogen receptor, progesterone receptor, and HER2 expression, limiting the applicability of several targeted treatment approaches used in other breast cancer subtypes. The two Phase 1 studies will evaluate leronlimab in combination with established treatment regimens and will incorporate exploratory biomarker assessments, including circulating tumor DNA (ctDNA) and PD-L1 expression, to generate early insights that may help inform subsequent clinical development.</p>  <p align="justify" style="text-align:justify;">“There remains a need to better understand how novel combination strategies can improve treatment for patients with metastatic triple-negative breast cancer,” said Paula Pohlmann, M.D., Ph.D., of The University of Texas MD Anderson Cancer Center and principal investigator for both studies. “PRE-I-SPY allows us to evaluate safety while simultaneously examining biological markers that may provide an early indication of how these treatment combinations are affecting the disease.”</p>  <p align="justify" style="text-align:justify;"><strong>PRE-I-SPY Study Design and Patient Populations</strong></p>  <p align="justify" style="text-align:justify;">Both studies will primarily evaluate the safety and tolerability of leronlimab-containing combinations while assessing preliminary signals of clinical activity and exploratory biomarkers, including ctDNA and PD-L1 expression as measured by combined positive score (CPS).</p>  <p align="justify" style="text-align:justify;">PRE5 will primarily enroll patients receiving first- or second-line treatment, while PRE7 will focus on patients receiving second-line treatment. Both studies will include patients with a CPS of less than 10.</p>  <p align="justify" style="text-align:justify;">Both study arms will use a de-escalation design that starts at the highest dose of leronlimab (700mg) and evaluates dose reductions based on a one-cycle, 21-day dose-limiting toxicity (DLT) observation period. Cohorts will include six patients each and are designed to potentially expand if no DLTs are observed in the first cohort.</p>  <p align="justify" style="text-align:justify;">PRE-I-SPY is a Phase 1 platform study designed to efficiently evaluate the safety and optimal dosing of new therapeutic agents and combinations for breast cancer. QLHC is the sponsor of the PRE-I-SPY platform study, while CytoDyn is providing leronlimab for evaluation in the two new regimens.</p>  <p align="justify" style="text-align:justify;">“An important goal of PRE-I-SPY is to identify promising therapeutic combinations with acceptable safety profiles that could potentially be evaluated in earlier-stage, high-risk breast cancer through the I-SPY 2.2 platform,” said Laura Esserman, M.D., Co-founder of QLHC and Principal Investigator of the I-SPY 2 platform.</p>  <p align="justify" style="text-align:justify;">Preparations are already underway for both studies, and enrollment for PRE5 is expected to begin in the first quarter of calendar 2027. Enrollment for PRE7 is likely to begin in the second or third quarter of calendar 2027. Additional information and updates on both studies will be provided in future Company communications.</p>  <p><strong>About Quantum Leap Healthcare Collaborative</strong></p>  <p>Quantum Leap Healthcare Collaborative (QLHC) is a 501c(3). It is a nonprofit pioneer that designs, implements, and succeeds at building and iterating creative and nimble solutions that drive meaningful results for patients. QLHC’s mission is to better serve patients by accelerating and innovating health care through approaches that challenge the status quo of science and care. QLHC’s efforts focus on achieving our long-term vision to improve human health for all through personalized medicine by bridging the gap between research and care. QLHC provides operational, financial, and regulatory oversight to I-SPY.</p>  <p>For more information, visit <a href="https://www.globenewswire.com/Tracker?data=eNSb8jVkkDvwxQQkKHnJqQOR7ZL6aZEEmf1fE-sVdQcG_wiM9cStSVqivz0PfsNCSVAKiiMMrheAESkNZKqYDuxSzPq37jBjezUdXYulOoGGDyymUIxaGZriwuen0IxV" rel="nofollow" target="_blank">https://www.quantumleaphealth.org/</a>.</p>  <p><strong>About CytoDyn</strong><br><br>CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p>For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=EsX8bMbXJYrg8cKMcvY2Oe04Hd2dFh3f0O8buykqf7NA6TUSvqz6GEn_HMz2IsGW73ZXLnA53AUuVK93knuE5PGLZXobPzEHJmldV6Q45xrVnZIoTZUCmv0qN3a15JXGjC-j37Umg5L3Q8YMMcVjsWk8iIs2AXG2q3yGYvee-GvCLAgslwrsZN0qqHio99AoXDEUQVp7ZFZjHn7Z2D39p14DsaEBuZ_cICffyCGX8CrYI8LWmM3RvU7EIm44sNHIL3e1morgYEQf1mhkehnRy6tRcKwyQNdycHqIO-KIjeOi-g62gQICzarpnTnqIsGkhYGUImcXpOGJC-0ilNxZi2VxZCyjf8fMKsuS-CmsZ4RopZ2cb-cBoBjOmStEWlbebOVegKnezI2cCeRNbvmyTlvQ3dwkRdyxZ858jvzUQpXaHt-MI87qhtyL9pCHLbmULSuAo2-W2wGULBbHPOEiQp_Adv2XLRND7mMYC07eezo=" rel="nofollow" target="_blank"><u>www.cytodyn.com</u></a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=YwdzZe0I0nyXXPbkLaxYstOkC_QAtcqgAjIZmapHf9z2_CSoe86Ru13EOOMG7SwM1e0MKWgJVL3Za-h5BwLh-qQYwKJalA9aaUvLQphg8E2tPr9-n2OF8R2BRVssuICIXPgfGcp8uITu-A9FNE_6b2Ju0Aq70oANIdvB3ZJlxuKuZMAvmtgSKu1PI0F5CxeSbDtvdV1wWaofMBxbH-22Ds6ZDfV_9DwTOb26DdR99-efF4i8Y2zYqeoIILN-WamsnB4pj_z3j5J64qXyhFIFw5SNvgZTtO7jn2SxEXlExYfojRM1zDEXu4Hccbg1Gddc0qhZXWJmAX0fXX9GLRjlsJIn4aIzGhLwig70Q0n1CHBDPpWee2t7D_rhLeneoaMsSgRdIDJbr6CQkb6gzMennmCfJnS3HFHJ3YA3nTiOCXNFTgIsOqs1LHGL6uIp-oC5" rel="nofollow" target="_blank"><u>LinkedIn</u></a>.</p>  <p><strong>Note Regarding Forward-Looking Statements</strong></p>  <p>This news release may contain forward-looking statements relating to, among other things, mechanism of action, clinical development programs, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p><strong>Corporate Contact</strong><br>CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=H_jFlxVqgS5TbwQlDpVieL8GKP08H2riXfhiDqOW-aYqU_Z-ljmhRRaYarZGSvjIDGKDf9A3l8nWXlG7Z5E9_kKzcEoIDAsKDZuz7y6EB-ycGSArc8vZXDCMvskmlw7mI4e56xfKOdbqmNb9xcU_yXLN3TBKbcIly-bupGDPTl3uG5sZjT9hdbhUXfHkz-Wlovnn56bEIYWeR_y_LYNq_5ObEldjhCXX_zygl-4yjPGTeVB6JFPvniCcl2j7BSH2eJBq7VEiHz_bcEFQfHDNIbPDm7aPwKmvdv9p5xvkxXwmYq1V1CGomklih8S54pDbiqQi5khI6iYmWMMXNaaw-YaR8fwbUMqzt1LL_HIn5nLsT0mmHLkAt0EnOqEVmGTViOr4wP6wCYuyoKzVAUQaZOTKG9WW5o4uB1IpSoOpz0ogCOz1mGjUxX6S8CPyCPxj" rel="nofollow" target="_blank"><u>ir@cytodyn.com</u></a></p>  <p><strong>Media Contacts</strong><br>David Schull or Ignacio Guerrero-Ros, Ph.D.<br>Russo Partners, LLC<br><a href="https://www.globenewswire.com/Tracker?data=zlzaC4xTj8c1bzRxrR4pxJqu4qSa2g74pSI553Fj6tVU6ttKOdQGYFaDQpN85qW-jnL3BZ4LbTs86VORenZcdNqfuqosO8KpNkkSlc0zHF_nXJ0C20Gsl-lhNFn36tvC0nWPAUX1H2hAIMEbHVL1Q8jfXgNmkqz7U91gNvSDJnb2AjRkz-nVQ7hWoDlBb9uufb0_KEZr_NBvUUr3CaRjQX3OQ3GuUeyVM81uOlWpWXx0WVfQCpo_NGIR53_SuH7pRnwl7IOcUUpLQeJHD2EW0KqRc4jS_8-AJKQe5dr8h1lpRPhHuFuCRMhUWD_EPTXzWhbKUVw36z0dIxAUSnTZfwVJ9xMxpAszrr-zvVRLa-cXdSldc3thTB0K_4oCQ0Hu2xx0Hh3R9yEjFIXqtOOFmIDZgnLJPlHklcGwr1yriD9Xj5TRnmRGrH_UGQisEQ7pjqc7d0-ede3pj5Xx50yC4c2ZcH_owARBAGLlJLH-WXKOewgNKtDHehc8EY1W0MtTW5imiIgZNhI6zCp2QmumUd5pqqTX3PerJrlqDj5XVUkm6KcHto0a8alfGnpoXwVK" rel="nofollow" target="_blank"><u>CytoDyn@russopartnersllc.com</u></a></p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
    <item>
      <title>CytoDyn Presents Updated Leronlimab Data in Metastatic Colorectal Cancer at ESMO Congress 2026</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/672/cytodyn-presents-updated-leronlimab-data-in-metastatic</link>
      <pubDate>Mon, 26 Oct 2026 08:30:00 -0400</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/672/cytodyn-presents-updated-leronlimab-data-in-metastatic</guid>
<content:encoded><![CDATA[

<ul>
<li style="text-align:justify;">Phase 2 CLOVER study enrolled 66 patients across seven sites in metastatic colorectal cancer</li>
<li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;">Updated data show universal CCR5 expression, early ctDNA reductions and favorable tolerability</li>
</ul>  <p align="justify">VANCOUVER, Washington, Oct.  26, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY)</strong> (“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), today announced that updated clinical and translational data from its ongoing Phase 2 CLOVER study (ClinicalTrials.gov Identifier:&nbsp;<a href="https://www.globenewswire.com/Tracker?data=OzE4dD5wDk9ssMW897Cavv7wlN8AsioJ8hD4dGTIsNjMYvG81O8IMSWLj2v_9TdXhTlXriCdQ4kU-eYUr-OdN3UdpeBQrlPfaNLQqvfHQdC_qWnHRrE5H-Qd2mztygj7" rel="nofollow" target="_blank">NCT06699836</a>) evaluating leronlimab in combination with trifluridine and tipiracil (TFD/TPI) plus bevacizumab in mCRC were presented at the&nbsp;ESMO Congress 2026, held October 23–27, 2026, in Madrid, Spain.</p>  <p align="justify">The poster presentation, titled&nbsp;“<em>Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study</em>,” was presented by Benjamin Weinberg, M.D., Associate Professor at Georgetown University on Sunday, October 25, 2026, from 4:00 – 4:45 a.m. PDT (12:00 - 12:45 p.m. CET), as Poster #820P, and included updated safety and biomarker findings from the multicenter study in patients with previously treated mCRC.</p>  <p align="justify">CCR5 is implicated in the recruitment of&nbsp;immunosuppressive immune cell populations, including regulatory T cells and myeloid cells, into the tumor microenvironment and may contribute to immune evasion in colorectal cancer. The CLOVER study is evaluating the safety of adding leronlimab to TFD/TPI plus bevacizumab and whether CCR5 inhibition may enhance anti-tumor activity through immune modulation. The study’s primary efficacy endpoint is objective response rate (“ORR”), defined as the proportion of patients achieving a confirmed complete or partial response according to RECIST v1.1.</p>  <p align="justify">“These updated findings continue to provide important insight into the biological effects of CCR5 inhibition in metastatic colorectal cancer, particularly through the integration of tissue and blood-based biomarkers,” said Benjamin Weinberg, M.D., Associate Professor of Medicine at Georgetown University.&nbsp;“The consistent CCR5 expression observed across all evaluable tumor samples, together with rapid, early reductions in circulating tumor DNA, supports continued investigation of leronlimab in combination with established therapies for patients with refractory disease.”</p>  <p align="justify"><strong>Key findings from the Phase 2 CLOVER study include:</strong></p>  <ul type="disc">
<li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;">
<strong>66 patients were enrolled across seven clinical sites</strong>&nbsp;between June 2025 and May 2026. Leronlimab was administered subcutaneously once weekly at either 350 mg or 700 mg in combination with standard doses of TFD/TPI and bevacizumab.</li>
<li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;">
<strong>CCR5 expression was detected in 100% of evaluable archival tumor samples (91/91)</strong>&nbsp;from pre-screened patients, further supporting investigation of CCR5 as a potential therapeutic target in mCRC.</li>
<li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;">
<strong>In 28 patients with available baseline </strong>and Week 2 ctDNA results, a <strong>median reduction of 86% in ctDNA was observed at Week 2</strong>.</li>
<li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;">Among the 32 patients with currently available safety data,&nbsp;<strong>no leronlimab-related adverse events led to treatment discontinuation and no leronlimab-related adverse events greater than Grade 2 were reported</strong>. No leronlimab-related dose-limiting toxicities were observed.</li>
<li style="margin-top:5pt; margin-bottom:5pt; text-align:justify;">
<strong>The TFD/TPI + bevacizumab + leronlimab combination demonstrated deeper ctDNA responses</strong>, with significantly greater reductions in molecular residual disease (MRD) from baseline versus TFD/TPI + bevacizumab at both 0–4 weeks (<strong>p=0.0005</strong>) and 0–8 weeks (<strong>p=0.0006</strong>), as well as deeper MRD reductions than TFD/TPI alone at both time points.<br>
</li>
</ul>  <p align="justify">“We are encouraged by the consistent CCR5 expression across evaluable tumor samples and the early ctDNA reductions observed in patients with available data,” said&nbsp;Jacob P. Lalezari, M.D., Head of Research and Translational Sciences at CytoDyn.&nbsp;“These findings give us additional insight into how leronlimab may be interacting with the biology of metastatic colorectal cancer while maintaining a favorable tolerability profile in combination with TFD/TPI and bevacizumab. The expanded biomarker data being presented at ESMO will help further characterize these observations and inform the continued development of this program.”</p>  <p align="justify">A copy of the poster will be made available on CytoDyn’s website under the <a href="https://www.globenewswire.com/Tracker?data=sA6mtGy4C2uJB6vuwJZvY7OE2YoHWTVtY2TsXeR7DhmJJFZZJYgGOww4vPhek41qylhI4kLpztVbpyK9_1cuoFiJ1CgFVP073U0VSn3P44pRHlMolYa_qwdhNRPduNkH" rel="nofollow" target="_blank">Publications &amp; Posters</a> section.</p>  <p><strong>About the European Society for Medical Oncology (ESMO) Congress 2026</strong><br>The ESMO Congress 2026, taking place October 23–27, 2026, in Madrid, Spain, is a leading global oncology meeting bringing together clinicians, researchers, patient advocates, journalists and healthcare industry representatives from around the world. The Congress provides a global platform for advances in oncology research, clinical practice and patient care, featuring new scientific data, educational programming, networking opportunities and innovation across the oncology community. For more information, visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=c4pSUBt0hEQ5QmvvnexaG7rCltW7Xgq1zp6X8fxHuLGFz2Xwi5AF5xxXW3Hh8lHqeNz-eqEAR9-Ro_hQDRwBiA==" rel="nofollow" target="_blank">esmo.org</a>.</p>  <p><strong>About CytoDyn</strong><br>CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p>For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=sUjC9AofO_GWwGBtcBYxVxh_JOmyLuYopovey0s23B2uJAx3gaTD4hp4hbKC_hMcQjFHnKv5Uj0CBy0g3PQKsMzmO1xR4EeFRLgF0yd04lnIj3tmRTD08lQQJnlL8IyVj5CFX9RQy66dDqkjLYXq6CSDPVZSrBgY4Cv_incaq-CdNOymk5j0sxgO1BRT3-bntC02PxXjlv4I97hC6wyGYOPmBgOeRjAVUETSMn0NtcYfL_BSJIqLWxtTEknQHR-hgCJ56vm1df8Y_K4dE2jBAjuC_7Ri_Si4wTiCQkjgtLXV59JmsLMRjAvq1dSaZtn3HatLypbFSrefOa70q8lRiQKiuypf4cdFrR2ZiAgXlJJ-JP1GDtlPuhGNaf2a3F1IYBO-aLo0bkvNHKAQhjO-8tKIzowrBUYWTXqRID9wPI7w41R5yr9BI1MvVijXcKEmF9BIccFYD4O0EIJmNGYg2WFreEZunE4Lw08cyqDsXls=" rel="nofollow" target="_blank"><u>www.cytodyn.com</u></a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=zVudaZZRcnVRM1MozuyHStu-JgvOPMxxWO2Iv4NBt3JhxMeWSlZadhoSNtvcRern6skGKHfUOn0YR5CAb_B-Fz7YdwVrHW93Y31mkqe4UOinkzc9GwFv2MEpL2EkBUzq_Arf2XzpnnBL1VWD1TuqLrD8QAMmfyd0ez_GszBZOEoBl4S2EvT-6kxgwtNcDeCqf_ttuB9TVNI2lhHYbeEC-x-ueHIekL7EGjW9jdGG11jzphol1T9HfROJVOgTEoRMQAKSQLQkiiUNgImrfChF3GZO9E6wcn62Se0cYzhdIQtfdOaR3mQ-b4tO1GU5g4sphibbdLLaamNCX21uQNZTAKahWyocHDI_VKDStp06tksZvtW5Vb8qO1CHJlwvzFw3GNCHvyjcnMZGvnuGirZjMB2eqbCNAqE_DGQfXLNwRF7kmUYpEJ0yHJldq63ymx_3" rel="nofollow" target="_blank"><u>LinkedIn</u></a>.</p>  <p><strong>Note Regarding Forward-Looking Statements</strong><br>This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p><strong>Corporate Contact</strong><br>CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=p9_Hg0i7emZEi5po3g2JissUmXXBSh3Ld7ksM6HmDJ_nYkxBR0QNv5mvt14XkCyBCIKQtUkNe6ZPgxprFLeDM4CcXv9Bntg1YIFmpvfrC3LfpISRdf9IoEn5s5H_okAN25Tc8Skvfmhv83qjDgnJEfMUOs1OE_am26v3RuUgjxXvQNAHMtKWYl0Je2RmazCpRAl8cn5dxG16eIup73BN1MujlcACl5xiBOaZxPIcWdbp2So-W0zSxP69nesvQqGgMB8EspL2cup3LR8G6zFdnbfL6hrI4LRFVag7zsBopJqd5E1hGseulu-hRbgajCcJeNCz4qA6-3LDV_YrT-4os0ZPAX5vMOqWxBzPn8a5h-oRMskUL-T7_Jb-SVuxmgmeegftu3BaLnuwArj5CDkqR8zF8XAgIDDz-udFi6g_AJUdadiGSXB0YMG3LEC7sUln" rel="nofollow" target="_blank"><u>ir@cytodyn.com</u></a></p>  <p><strong>Media Contacts</strong><br>David Schull or Ignacio Guerrero-Ros, Ph.D.<br>Russo Partners, LLC<br><a href="https://www.globenewswire.com/Tracker?data=bpZ1MypfiZZ8Iq8nPk5hcp9BGvrHf6JOdcgTlg_DjrM3N17CViWZdoGIcqx6R7YeC9PN4E0qwuGJsWeHj9xFgIZbDBnn8jn8AXTsZ_usIpOSmCp42canjXoKB2_oPE-DcYaYOCoGGsGqZH9gpf2B12LVRjN15tLYVERYLoIgOoLuFGlxbNyHpZnqkNrfDQiJCTIt64inP5klYF3oH5udxNEbQwPKKIllcqPTY7fmbcVs9sKkRBD-Cz4w4Agz03p8OIWydwkPPHEW7VvjH-3VkEixgngXGH3E_Pr6Qgx-uKiUH1hchOmZL4T0VqilwuKq8mVd7i9e7u607vWB2OXHHBwAyG2TuLWQOxQuEpJCxVQaOpJnSKouAM5RlXvkw2xI4RgDc_ro_63SJM4ZdcwB1MAFj49OUwRyIGQ1oKj3l-SRDIGklb5CfPaurC0Ga3xwP1KT3qkgawPIcprdI7Z7OHO-LJWbmHf5ZYYE63bTmVVX__6Oh4K6E31ksG6BIDcNgOVK6xxC1LQKNXKe5UIE1TQMUbHMTga8hJ3vpLucIypmNUyIhzCAB18I1XuCZbHd" rel="nofollow" target="_blank"><u>CytoDyn@russopartnersllc.com</u></a></p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
    <item>
      <title>CytoDyn Appoints Robert E. Hoffman as Chief Executive Officer</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/671/cytodyn-appoints-robert-e-hoffman-as-chief-executive</link>
      <pubDate>Mon, 19 Oct 2026 16:50:00 -0400</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/671/cytodyn-appoints-robert-e-hoffman-as-chief-executive</guid>
<content:encoded><![CDATA[

<p align="center"><em>Dr. Jacob Lalezari to remain with Company in scientific innovation and discovery role</em></p>  <p align="justify">VANCOUVER, Washington, Oct.  19, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY) </strong>("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), today announced the appointment of Robert E. Hoffman as Chief Executive Officer, effective October 20, 2026.</p>  <p align="justify">Mr. Hoffman takes over in place of Dr. Jacob Lalezari, who had served as Chief Executive Officer since November 2023. Dr. Lalezari will remain with CytoDyn as Head of Research and Translational Sciences, where he will focus on identifying and advancing new opportunities for leronlimab in solid-tumor oncology. The leadership transition comes as CytoDyn prepares for its next phase of clinical development, with a focus on advancing its oncology pipeline, pursuing regulatory milestones and exploring potential strategic partnerships.</p>  <p align="justify">“Robert’s expertise is aligned with what’s next for CytoDyn as we look to 2027 as a year of clinical results, regulatory progress, and renewed partnering opportunities,” said Dr. Lalezari. “While our team executes the business plan to build on the very promising results from the CLOVER study, I will focus on identifying new opportunities for possible pursuits in solid-tumor oncology.”</p>  <p align="justify">“We are entering a transformational period for the Company, with opportunities to build on the scientific and clinical progress achieved in recent years,” said Mr. Hoffman. “Jay has played an instrumental role in advancing the Company and helping establish a clearer path forward for leronlimab. I am grateful for his leadership and look forward to continuing to work closely with him as we focus on clinical execution, financial discipline and positioning CytoDyn for its next stage of growth.”</p>  <p align="justify">The Board of Directors appointed Mr. Hoffman as Chief Executive Officer in consultation with Dr. Lalezari, who supports the transition and intends to continue to support the Company’s scientific efforts. In addition to assuming the CEO role, Mr. Hoffman will continue to serve as the principal accounting officer of the Company.</p>  <p align="justify"><strong>About Robert E. Hoffman</strong></p>  <p align="justify">The Board of Directors appointed Robert E. Hoffman as the Company’s Chief Executive Officer, effective October 20, 2026. Mr. Hoffman first joined CytoDyn on May 15, 2025, originally serving as its Chief Financial Officer. Mr. Hoffman is an industry veteran with decades of financial and leadership experience, having served in a number of biotech executive and board roles. Most recently, he was the President, CEO, interim Chief Financial Officer and Chairperson of the board of directors of Kintara Therapeutics, Inc. Prior to that, he served as Chief Financial Officer and Senior Vice President of Heron Therapeutics, Inc., Chief Financial Officer and Executive Vice President of Innovus Pharmaceuticals, Inc. and Chief Financial Officer of AnaptysBio, Inc. Mr. Hoffman started his career at Arena Pharmaceuticals, Inc., rising through the ranks to Senior Vice President, Finance and Chief Financial Officer. Mr. Hoffman currently serves on the board of directors of TuHURA Biosciences and Fibrobiologics, Inc., and has previously served as a director of several public and private life sciences companies, including Esperion Therapeutics, Inc., ASLAN Pharmaceuticals Limited, Saniona AB, Kura Oncology, Inc., CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc. and Aravive, Inc.</p>  <p align="justify">Mr. Hoffman is a former member of the steering committee of the Association of Bioscience Financial Officers. He also formerly served as a director and President of the San Diego Chapter of Financial Executives International and was an advisor to the Financial Accounting Standards Board from 2010 to 2020. Mr. Hoffman holds a B.B.A. from St. Bonaventure University.</p>  <p align="justify"><strong>About CytoDyn</strong></p>  <p align="justify">CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p align="justify">For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=je1k0rfwwbH6w5OgHOMGWIwY61tOAoUbNzs1RVN_kgToBNXOY01GSum-ksWLwoQ1iCipoDldqdQsthIofMqeVE7djv_TEJmmftYqmi3SRp4=" rel="nofollow" target="_blank"><u>www.cytodyn.com</u></a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=yWFVT4jicpln8lltU4g-LbU10n8bVHmFDENt84IizYI5qBpQPlfvMtHDV72kyXFAsS8BROkfYbW_0lUj0_rbzCkj6WEPr6_kbPpNVJ2SuOCwGwOwuCBnURD2NzBUO9m-" rel="nofollow" target="_blank"><u>LinkedIn</u></a>.</p>  <p align="justify"><strong>Note Regarding Forward-Looking Statements</strong></p>  <p align="justify">This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p align="justify"><strong>Corporate Contact</strong><br>CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=SMKHysHzMA-cavUqlNAcrYQXXQRqWfqMHp_bhzT7cFwR6fNpH8XCT-978g21DeDAcI50gsuxXJQL-AXMON6GVlbi0s57YB4OUrjVEtoqt9cPcCPGFYPG_wtZaGBcPFxar5iiHdkRnTOwwDTz42pHlVeL2CRLlK9tWfLmo7OH4UhVqzbURTtBj9N2MC-nEGF3CPKKUBYqNrkjVKdxY-wOSUz3defVTV3vi9j8CXzjdre67kykDkH-5dlz6ZoIPZqDlTM14J2dFB9HKZygO8Yf-lB3O6MWgEW7DcOmD8Wqh0kx7FE_1ejzOY0X8pVHbHL_NPEVnh6AFQm-wPyWUaUQ8izNqHXwu0zeGcRwCeuaKRblcpnciWEL7VXKDcFbX0X_b-vsPDQ3RlPXDJtCpJJLEn8LRtItQLXDRZaPbBbugPUH09qbO56m4kyXKHDZvRWU" rel="nofollow" target="_blank"><u>ir@cytodyn.com</u></a></p>  <p align="justify"><strong>Media Contacts</strong><br>David Schull or Ignacio Guerrero-Ros, Ph.D.<br>Russo Partners, LLC<br><a href="https://www.globenewswire.com/Tracker?data=W4GlBeiuuKRinw0tDme6a1eaAkWm_al4xtIi2ylh3SrwaRmNWM0P6rTHz19jBv1JKqEJw-oiWuMF2E2XyHVv9ZwOi2cBQW6bfGVgKrMwgX2jL0HpeLbmo7i0-1vNJ10lD1_SAfCmeQIyR1jIRA97PL8cfgFWMEJRg2xV34JDNSh-EhX6_nJ0Q351AR23NYpZf7mWV1_COq6iAMao6jxsdjK9XNMCGubsZNkQCYLREHWTLq5RjiPOWscr6o6Uwonif_wcrLCtP_hJAWajZeLdgRfl066HgS6743s2EnFfgPfrawlnEhcKdkOgI1R7C-jQA0wWZXso625mXeqp_jnmEqxAJFWvob9BN6x7bihUCTg5bel6W6lz9E14Sd21n51dg3KtMla6BaTETN41Xb97MWklQl-XVrlh4YkgK-_P6fMlYVetZgSrVbolookWUajC6V7lcM1JH2_Ez4VEaIZTbJvygXp0VyTRpnmyW1WHAcvkgDDFoJ81PP8c0ztbyjGtG-Ink-1NJDZGmhOu-GJBhiJCSJa8pfrF1RiHHomZeckPoCe9et4rtAvmbQy7fIXG" rel="nofollow" target="_blank"><u>CytoDyn@russopartnersllc.com</u></a></p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
    <item>
      <title>CytoDyn to Host Investor Webcast</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/670/cytodyn-to-host-investor-webcast</link>
      <pubDate>Thu, 15 Oct 2026 08:30:00 -0400</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/670/cytodyn-to-host-investor-webcast</guid>
<content:encoded><![CDATA[

<p align="justify">VANCOUVER, Wash., Oct.  15, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY)</strong>&nbsp;("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (“mCRC”) and metastatic triple-negative breast cancer (“mTNBC”), today announced it will host an investor webcast on October 19, 2026, at 1 p.m. PT, to provide a corporate and clinical update.</p>  <p align="justify">The investor webcast will highlight CytoDyn’s latest scientific, clinical, operational, and financial progress, as well as calendar 2026 priorities and upcoming milestones. Dr. Jacob P. Lalezari, CEO of CytoDyn, will be joined by Robert E. Hoffman, CFO of CytoDyn, and Pashtoon M. Kasi, M.D., M.S., Medical Director of GI Oncology, City of Hope Orange County, Irvine, California. Reny Aniline, Senior Director of BioPharma Business Development of Natera, Inc., will also participate in the webcast to discuss the recently announced strategic collaboration between Natera and CytoDyn, and to provide further context on the early ctDNA observations in CytoDyn’s CLOVER study.</p>  <p align="justify" style="padding-left:40px;"><strong>Date:</strong> Monday, October 19, 2026</p>  <p align="justify" style="padding-left:40px;"><strong>Time:</strong> 1 p.m. PT</p>  <p align="justify" style="padding-left:40px;"><a href="https://www.globenewswire.com/Tracker?data=hQgQXowLsELrtFquGdmxIlBbv1PwkisJ3OtZMr0vCZgjQpLPWSSGJiq6l1VZsQc4h3XmgJBC74Cyta5xjg7xXdMp6orMcLbluywga0D3tARaZCdivzm6103812JD3JNNJz0G8t6uYzoGsGo_DP_MQ55CDWk0D-dl9Qi3lt_dyP06p0YocaPSVe-j7sqdDimS" rel="nofollow" target="_blank"><strong>Registration and Access Link</strong></a></p>  <p align="justify">This is a livestream presentation. Attendees are advised to log in ahead of the start time. The Company will host a live Q&amp;A session during the webcast; questions may be submitted in advance to <a href="https://www.globenewswire.com/Tracker?data=p8HIV9lleMTzbNXQhH2AzXQ1pgqNqfdJByuA8X7hVSxsuiHL5giPXvVLiqz6ZTs7NkU_6dw-pH_a9tAauSDzYA==" rel="nofollow" target="_blank">ir@cytodyn.com</a>.</p>  <p align="justify">Following the conclusion of the webcast, a replay will be available for approximately 30 days in the <a href="https://www.globenewswire.com/Tracker?data=dFLJssccrXO-PMeY0nKxwHGHfNMtTt4Eij6cmVvsjnUAMqypwATblV1_kcaohxFQJnjCjI30ro8LcWo9lgFJPQM-oq9xhlqvqVNR6fCaARCxfKc0wp2lA1_LYmDDS679" rel="nofollow" target="_blank">investor relations section</a> of the Company’s website.</p>  <p align="justify"><strong>About CytoDyn</strong><br><br>CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p align="justify">For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=_o5aqzLe2Ss1NzDZKOk5ftPF5N8OEXoc9lGM7phemwzjHhhUlAy_Igyyaxk1voFwI_4gFdXi7SFtwU9WNTg4KCe0JTZ0RNmNIgU8eaWAPwpPWMgQ0UQNKMzgNtBfrv3YUntc2csCQq4WT2G53e1b_HR35X4sNIitUDi_dc-LYspA4gTVU29F8iLjf4nP0krAB9ZOCVsBh3u1OjhKd9vRCR3UffecS81YMGrWO4pnbWarLLd1yOVoDKAtxC3qzmQu1C_jJP6fJ5W0FifcFFk4cHmqZZNlJPAJBbLlQi4iGBnW0FuMWendi7QPUa_f27VVdfuJrR-xlILS_FV--3ldSgOkaciJl0XxPTUpmry41mh24xozHtvcVEq8DENWg0sxzGO_q4onxw8VTbb9PFDGO4uRYKDpL3WcQYnunuJDyDHeDaQoXq9voYmHjW3ZqJ1sdYV6ZDLqcLCjgklHcVJW9-cl4e7Rr2GN3bDdMnRFfNQ=" rel="nofollow" target="_blank">www.cytodyn.com</a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=Q3-wVlaeC7tviUnocrK-Q4W4QT5GrghmB1MfzO3eYIkwRJ5GLalsr6LwJ7UqBiUcglD4kVD3XzGnI_VC0ZzXlnwLRFufFxQpniRXCmFJ4B0brLudasd8ssRjch7Hh-2tf-amA-T1LCjpCysgnr49WrFnUDcOSIdQKyh0OyDgzUFwWDU9VkknHmtxtIpujDif6BH3AbnZUrFlmfCrg1-XhDmWc1dwRJg3buAJXmxlSaCXihNGTxCeXjNUV4hEz32vPtWRS0A1rZ-MCqvOPKRA4gGG4CszVOfsIbHd9vJsHd9ehFCFTl1lVrBLjqpJ8e3FpKIll_ShPHLT0llUQhChBZVoN0zeZpR9aNimBBx46NItC8lpgQQQ_NK5cMOZnx_y9HMOB0NwINR2ANbK66MM1maewPHOpM2UwirqbpSr6FLWPZKagPqtKEEhU050R_a1" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Note Regarding Forward-Looking Statements</strong></p>  <p align="justify">This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p><strong>Corporate Contact</strong><br>CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=p8HIV9lleMTzbNXQhH2Azb6eqY8nLuPdVkykjcoXAi3GC6SBkLuRHWgEjLTrQWAZGnNXlUnJ4lBia9iRcBQaZaBU87h2NG47D0yiFAFqD1-Zpe8fZj-awXCd62SeHhUlgqImh-ORq0B6O8hLxF4O_BFVEHvCE2DbsvZI_fllq4e3S0b-DPeiPnIgs-XKj7NtVtrEYXNh3r85-sBm_lJlZ9JQ3mbgvhC-vZtlwnmTJKsTuh3WKxAhc-AXbeZXMNAvyfLgfdhyk8EUj-4MvsQpIE03V6cWF_2lapbQjYg517pWBRbuMdLi3xp3N6fdwNYgOUWt4YpBCL7OQVfZQqwfZN5A3kWD7mvUv4b28RHDEx7hVG04IfGC4QEoRDX8JFZGdVuyFcatMk1-NdpQAHG4wG_rrT0arCNiy1jcyHQCf1Um8lQTstqIBVC04zZo0zmL" rel="nofollow" target="_blank">ir@cytodyn.com</a></p>  <p><strong>Media Contacts</strong><br>David Schull or Ignacio Guerrero-Ros, Ph.D.<br>Russo Partners, LLC<br><a href="https://www.globenewswire.com/Tracker?data=zCPyXldNsctNAHMEQAG9hu4UgTQMmgqVIPMCYuF7E7VVRaICkBwl36wnWBq5edmqlLqDqIspsjNWSGi8VSxwo0dbSuXz2LE4vvv82yjBrA48j7TogorlmYfJFJRP5lkQs8coplzJ0C7LRhapahnKEQ1t-TaJjD59LZFzL80it9I6cBlg3Jp8xxsaIg1iO5vOJQqXe0dUG3zEU_iSiJOCaTo0eng1G1IqNw8P2zq8fNW7T3qxVRXcNocphTGEKGeQCPO1bazOW55HHlXfqOs1gfbdCoxh5Zxen9rprP2kSsJKeNWGvC1XfuZZcVmLXm85vLXAWiX3XNf_aEJ4wr_LYDswMmxSZHjB8k3yiQAB2EFUHlHvI2MvRi8fGaUeDmMBUuo0oikZTu2vgdtMMG_PohWTMeneU43zZpByvoDLNR2ru7yxngSRPLsYDZk2oQlp_uEiwa3GNajNzQXpPCBX-AypdKFWR0uH2NCXrJT-LMDGIvMU58gKNNr5K4hHl1eqTzbvf1_V6vu1PPIohQS6MSLwQ5gd32b5m5xuvc2tStJ1LkGVq__PNWSzh9fL7NwB" rel="nofollow" target="_blank">CytoDyn@russopartnersllc.com</a></p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
    <item>
      <title>CytoDyn to Present Updated Data from Phase 2 CLOVER Clinical Study at ESMO Congress 2026</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/669/cytodyn-to-present-updated-data-from-phase-2-clover</link>
      <pubDate>Thu, 08 Oct 2026 08:30:00 -0400</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/669/cytodyn-to-present-updated-data-from-phase-2-clover</guid>
<content:encoded><![CDATA[

<p align="left">VANCOUVER, Washington, Oct.  08, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY)&nbsp;</strong>(“CytoDyn” or the “Company”), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple solid-tumor oncology indications, including colorectal cancer (mCRC) and metastatic triple-negative breast cancer (mTNBC), today announced that updated clinical data from its ongoing Phase 2 CLOVER study (ClinicalTrials.gov Identifier: <a href="https://www.globenewswire.com/Tracker?data=zXl6W03a3bC5VmbVS5_fGqp6C96uGh6b6KccySKBl6XaJOu57nySyZOQ7LzmxrOudvXWfSL5LbxrcVb-rRYYP3n4_KvRRSFJMnvIXX-G7Au3TMeVfc5jPSbUPLQPK-4q" rel="nofollow" target="_blank">NCT06699836</a>), evaluating leronlimab in combination with trifluridine and tipiracil (“TAS-102”) plus bevacizumab in patients with previously treated mCRC, will be presented at the ESMO Congress 2026, taking place October 23–27, 2026, in Madrid, Spain.</p> <table style="border-collapse: collapse; width:100%; border-collapse:collapse ;">
<tbody><tr>
<td style="vertical-align: top ; ">&nbsp;</td>
<td colspan="2" style="vertical-align: top ; "><strong>Details of the poster presentation are as follows:<br><br></strong></td>
</tr>
<tr>
<td style="max-width:5%; width:5%; min-width:5%;;vertical-align: top ; ">&nbsp;</td>
<td style="max-width:15%; width:15%; min-width:15%;;vertical-align: top ; "><strong>Abstract title:<br><br></strong></td>
<td style="max-width:80%; width:80%; min-width:80%;;vertical-align: top ; "><em>Leronlimab (LRM) in combination with trifluridine/tipiracil (TAS-102) plus bevacizumab (BEV) in metastatic colorectal cancer (mCRC): The phase 2 CLOVER study<br><br></em></td>
</tr>
<tr>
<td style="vertical-align: top ; ">&nbsp;</td>
<td style="vertical-align: top ; "><strong>Presenter:<br><br></strong></td>
<td style="vertical-align: top ; ">Benjamin Weinberg, M.D., Associate Professor at Georgetown University<br><br>
</td>
</tr>
<tr>
<td style="vertical-align: top ; ">&nbsp;</td>
<td style="vertical-align: top ; "><strong>Date and Time:<br><br></strong></td>
<td style="vertical-align: top ; ">Sunday, October 25, 2026, 12:00-12:45 p.m. CET (local time)<br><br>
</td>
</tr>
<tr>
<td style="vertical-align: top ; ">&nbsp;</td>
<td style="vertical-align: top ; "><strong>Poster ID:<br><br></strong></td>
<td style="vertical-align: top ; ">820P<br><br>
</td>
</tr>
<tr>
<td style="vertical-align: top ; ">&nbsp;</td>
<td style="vertical-align: top ; "><strong>Location:</strong></td>
<td style="vertical-align: top ; ">Poster Area, Hall 5, IFEMA Madrid<br>
</td>
</tr>
</tbody></table> <p><br>“We are excited to present updated findings from the CLOVER study at ESMO and share additional clinical and translational insights from our metastatic colorectal cancer program,” said Jacob P. Lalezari, M.D., Chief Executive Officer of CytoDyn. “These data will contribute to our understanding of CCR5 biology in colorectal cancer and help inform the continued development of leronlimab in combination with established therapies for patients with difficult-to-treat disease.”</p>  <p align="justify">A copy of the poster will be made available on CytoDyn’s website under the <a href="https://www.globenewswire.com/Tracker?data=lsVMzXrQ8a57k94EfFZ7SE6wSGpJuMxK-irVqMHHj0kImGSSxxpzF7geI9h12mk-ibrpfc9yg76CTfMjzwS_LOsunDBTZfdZqttuIBklM-5YYzhNGok_U8Xty7MHPKtu" rel="nofollow" target="_blank">Publications &amp; Posters</a> section, shortly after the presentation date.</p>  <p><strong>About the European Society for Medical Oncology (ESMO) Congress 2026</strong></p>  <p>The ESMO Congress 2026, taking place October 23–27, 2026, in Madrid, Spain, is a leading global oncology meeting bringing together clinicians, researchers, patient advocates, journalists and healthcare industry representatives from around the world. The Congress provides a global platform for advances in oncology research, clinical practice and patient care, featuring new scientific data, educational programming, networking opportunities and innovation across the oncology community. For more information, visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=nmIISYcYxskhuXK0gVuSC5wBybdtjisc_OlnJE4ymEBdU7Qr3bf0A3h5Exo7xeByzHJ6MUNfvS64SMSszBY_lA==" rel="nofollow" target="_blank">esmo.org</a>.</p>  <p><strong>About CytoDyn</strong></p>  <p>CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p>For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=McQlzIKxN5cg8s7lHEUpZJEC-KPTuvIBOzh8YAzySTzeDxL7eDHG7-eDzWUwj0mOeVO5QBe2reuRa0_LZuxfdkuAvMBCMQAZZ2xuIdJBdSc=" rel="nofollow" target="_blank">www.cytodyn.com</a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=S9sJH_RqMwXlqrXxK1TSa8ooPcBNnd0UohNbL5Jo5mvnbJfkzYxqlm5yJZcf4xeq6oOXYkn2Stjsncye99QpSt0NdIOh-MSFdQLxNIORHB0=" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Note Regarding Forward-Looking Statements</strong></p>  <p>This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p><strong>Corporate Contact</strong><br>CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=Svmpy087BLGw3IjBYJZOyZWXLrrJlEKJTvPLxliigLjlLjd2A6z2rml72skcU06I8tMrdtDbP7xYW2fohcRqm5DrXkCozGj_6ZphhlL6-dpm_fT24Xbe5bUnb5XHmFKeXcaZsdm6g_N-yepgg7wkeJmGAitBmYdYL7jhES_E8F6uCgqVrk0sTGrf4ZHMaQ9j3ecmXEGKL54-cMZOxNkah5rTFrVlVRIC5u7Yr8rnoPAwOHuIyDUMjKAYwAhm38dNLKca9cAAaq8pgzTj3lLhpjKgRN0sAUfAEXIfyZBC1rvSBf8mvfcgDpLOHMr6v0f2fiuYjQyZgDkdSmPFdAFdlYTxwrVgNJhWAYDXVDACOAwDwq0KMZOWbqPFMrqPP67hjtKdI7WQ6qgCN9o2oYl8ks23XC46ED_jXadcLeTb3tM77d1_j8gmo0hGSI97a8qL" rel="nofollow" target="_blank">ir@cytodyn.com</a></p>  <p><strong>Media Contacts</strong><br>David Schull or Ignacio Guerrero-Ros, Ph.D.<br>Russo Partners, LLC<br><a href="https://www.globenewswire.com/Tracker?data=mmNF9wa7jD16l4sqNo_MO3Aj2ivHzVS181HlerTFdrHvNlgPIofrBXnk90OuG3mgt52dg8TwkD-6eN_Q5IiqmAj3epK_LG5bXdKaJhlCQVLkHvlAoEa6RIkLIX2-cfRW6J_T425Ch64gX9-_tpwwUH1K4q9fw2lWshU-2n546f4tZDfW82LGGAO7qln8KdJSX1Y8FjB0rhu7MV5Psp1EVqcPuBbp4Vq-bEI0tJPLrb1yT03wfC8NXP_bBRO4Gw0iwMUGZx-16l-qfZXbfm3OSH9U1BOI6ayEqn1uYgq6SDpNPa2ASggoe3y2lSCtsoxHcIguHQxbJxyakd-sx0yLET3BzLsDBHLOXQRxARL8rhr3oLr8hQeesVqgzDvt0ZCr7UWVaFGBSMdAYk3FKzV2C1coJSmrnYSx7In71ohnT6rdnPoxv8sOOxAa_s0dCJfl41zsp_1fXVyDaCHpW9qWDm2ecXG34OD07g_EkXKaWqH10NsOrx0HZM9UFCdBJjcoGZsYX-8r6BJ146f9R2ij_okUppWAXY3B51V6NTGDHGVzChWfKPpHkbvPgGoHcW6A" rel="nofollow" target="_blank">CytoDyn@russopartnersllc.com</a></p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
    <item>
      <title>CytoDyn Inc. to Present at the Life Sciences Investor Forum on September 17th</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/668/cytodyn-inc-to-present-at-the-life-sciences-investor-forum</link>
      <pubDate>Tue, 15 Sep 2026 08:30:00 -0400</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/668/cytodyn-inc-to-present-at-the-life-sciences-investor-forum</guid>
<content:encoded><![CDATA[<p>VANCOUVER, Wash., Sept. 15, 2026 (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY)&nbsp;</strong>("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including metastatic colorectal cancer (mCRC) and triple-negative breast cancer (TNBC), today announced that Robert E. Hoffman, Chief Financial Officer, will present live at the Life Sciences Investor Forum hosted by VirtualInvestorConferences.com on September 17<sup>th</sup>, 2026.</p>
<p style="padding-left: 40px;"><strong>DATE: </strong>Thursday, September 17, 2026</p>
<p style="padding-left: 40px;"><strong>TIME: </strong>12:30 PM PT / 3:30 PM ET</p>
<p style="padding-left: 40px;"><a href="https://www.globenewswire.com/Tracker?data=PO6U71pwBaW1YTvXQrvEcR1PHDdy41eXup0KSXZkaXN4VbMXw-KKqXoMsJOrrWtbeg5vz-THSYDV78oIxODEiefdbFdweFVHbZ8N9b9hnMxu2NX-0zeerSuCGaQOfaJYE7B3Kye1rTaQGzbEpygbUIoC5ePt-9mM168FbdoiZsR7NlLO2srf4rgXIpWEQaDx" rel="nofollow noopener" target="_blank"><strong>REGISTER HERE</strong></a></p>
<p>The event will be conducted as a live, interactive online forum, offering investors and industry professionals within the life sciences community the opportunity to submit questions to management in real time. A replay of the webcast will be available following the conclusion of the conference.</p>
<p>It is recommended that online investors pre-register and run the online system check to expedite participation and receive event updates.</p>
<p>Learn more about the event at <a href="https://www.globenewswire.com/Tracker?data=4AFWNATvvgyxAoe1Ansv8RmPPAI48rHdhr1lDo5SuPgkFxKrY55zFCpAI_sbtK_2Jol_mRD3qUPdKuDzjP7zUNtEqXUu1Y5B5st9joLCfTaxX8FRKwiXP1zu89bQ4xh0Ub8J-EvymtLPdxNEfGQ43g==" rel="nofollow noopener" target="_blank"><u>www.virtualinvestorconferences.com</u></a>.</p>
<p><strong><u>About CytoDyn</u></strong></p>
<p>CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>
<p>For more information, please visit www.cytodyn.com and follow us on LinkedIn.</p>
<p><strong>About Virtual Investor Conferences<sup>®</sup></strong><br>Virtual Investor Conferences (VIC) is the leading proprietary investor conference series that provides an interactive forum for publicly traded companies to seamlessly present directly to investors.</p>
<p>Providing a real-time investor engagement solution, VIC is specifically designed to offer companies more efficient investor access. Replicating the components of an on-site investor conference, VIC offers companies enhanced capabilities to connect with investors, schedule targeted one-on-one meetings and enhance their presentations with dynamic video content. Accelerating the next level of investor engagement, Virtual Investor Conferences delivers leading investor communications to a global network of retail and institutional investors.</p>
<p><strong>CONTACTS:</strong></p>
<p><strong>CytoDyn Corporate</strong> <br><a href="https://www.globenewswire.com/Tracker?data=UxLahRXV1hkGeGd4Ci13mh2n7oEgRQaO5TgjlGBP83U2l-RjaLf9898kY4Dv_O5jIMX7EmnfpwjkYrsRqTyySWQw0aYjqysUdihhzCYEqi2FcYCjk_61jBcu6nipzBlvHxPvEae3TLlu8yuf6S7aNhdNeeIC92Olabrw0UjFfcS7tirTs89hhufuGCmjIDDxYrBO9qnM7CwC6xDyEYumhZfcOQcZHS7zuAnB9zghikU=" rel="nofollow noopener" target="_blank">ir@cytodyn.com</a></p>
<p><strong>CytoDyn Media</strong><br>David Schull or Ignacio Guerrero-Ros, Ph.D.<br>Russo Partners, LLC&nbsp;<br><a href="https://www.globenewswire.com/Tracker?data=ThfR2wpCnsre2xOwbcjhwb3neP90NxSyVLzwsP48OBy10tN5qUTdDmK_l_N5Pu-QbIwNxWnlq5oky2OYH6UTDgBlVomg47SLmjLKaszRxVP3jrf1y5LXLZEGEw--cRFCuBCai7dLDgGGVRgOkzJTlnMOJNLAZ4rocOCot2sKTZUKWPZJtv-Gvo87RZjoDr9yPOfz-NaGpBcOdN31ty3gRBdv8Zsnl3t2Xmw2FznmyFS0KeWqpZPgBumAdvY8v9pFZpRCj4mmx-54n8vPJbRjfM9FLPM-UddzNNRdhDCowbnepv5bdaBBbTr54Icgq6gw9Sdoh7wnld96tfb9q9MuD28SQ0ReR3cKR26X9oPUCvMRxnn8pX9UeTVwaXcSP9_-QwvD5PJQJ_smvmS5Oyng8qHbteJDHRyTIZN5OkNP5vy6Crj1UPUOom6DTRvHww2-tkTte3NtFSxqAn8HnL8POclbU99Df0V0qvkI1pKp0T8NBbPVrYIJ6YiqwFvA7ixk_DMvpPitY371wOFyMyO_HA0vYIyFXYlmLiFXohKO0jbzxbmgsnmfmpLKQqloSYSC" rel="nofollow noopener" target="_blank">CytoDyn@russopartnersllc.com</a>&nbsp;</p>
<p><strong>Virtual Investor Conferences </strong><br>Greg Young<br>VP Corporate Services, Investor Access<br>OTC Markets Group <br>(212) 652-5958<br><a href="https://www.globenewswire.com/Tracker?data=9VunYoCi55vXDB5zffPZJ3y7x1xqblAbTH2KiG1Jw08JQxvazqmuzUOaYyNxT6CLm0ILvk2fg0tdByPPnMtY1auy9Uof3haindFUcZtDWoQ=" rel="nofollow noopener" target="_blank">greg@otcmarkets.com</a></p>
<br>
<p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/861fb541-7064-4cf4-a563-37472ff71760"><img src="https://ml.globenewswire.com/media/861fb541-7064-4cf4-a563-37472ff71760/small/social-media-vic-announcment-2-png.png" border="0" width="150" height="100" alt="Primary Logo"></a></p>
Source: Virtual Investor Conferences]]></content:encoded>    </item>
    <item>
      <title>CytoDyn Closes $16.5 Million Financing to Fund Continued Development of Leronlimab</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/667/cytodyn-closes-16-5-million-financing-to-fund-continued</link>
      <pubDate>Tue, 01 Sep 2026 08:30:00 -0400</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/667/cytodyn-closes-16-5-million-financing-to-fund-continued</guid>
<content:encoded><![CDATA[

<p align="justify">VANCOUVER, Washington, Sept.  01, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY)&nbsp;</strong>("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple indications, including triple-negative breast cancer (TNBC) and metastatic colorectal cancer (mCRC), today announced that it has closed on a financing of $16.5 million in gross proceeds, with Paulson Investment Company acting as placement agent.</p>  <p align="justify">The demand from investors reflects confidence in CytoDyn’s clinical progress and its versatile development strategy as the Company continues to advance leronlimab across its oncology programs.</p>  <p align="justify">“The successful execution of this financing demonstrates continued and strong investor support for our clinical strategy and the long-term potential of leronlimab,” said Robert E. Hoffman, CFO of CytoDyn. “We are encouraged by the continued commitment of our existing investors, as well as the strong engagement from new investors, which we believe underscores growing interest in leronlimab’s potential in immuno-oncology. With this financing expected to fund operations into the second half of 2027, we are well positioned to focus on clinical execution and the pursuit of strategic priorities that we believe will create meaningful long-term value for our shareholders.”</p>  <p align="justify">Net proceeds from the financing are expected to be used primarily to advance CytoDyn’s clinical development programs, including ongoing and planned clinical trials, regulatory activities and data analysis.&nbsp;The Company may also use a portion of the proceeds to support manufacturing readiness, regulatory and compliance infrastructure, and general working capital.</p>  <p align="justify">For additional information on the Company’s historical financing activities, including key terms and conditions of related agreements, please refer to CytoDyn’s filings with the U.S. Securities and Exchange Commission, including its Form 10-K filed on August 31, 2026.</p>  <p align="justify"><strong>About CytoDyn</strong></p>  <p align="justify">CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p align="justify">For more information, please visit <a href="https://www.globenewswire.com/Tracker?data=Ki8Je9x92YIT1wq0uuZrs43-u5W5XZlxpby_lmjX8e6Q_vynWFmebWKazfHI7osj2nZqhTsDJWKnfVVayORFAQ==" rel="nofollow" target="_blank">www.cytodyn.com</a> and follow us on <a href="https://www.globenewswire.com/Tracker?data=DmCqDW5iW5YcDN61l-Baq927Sd7yz461Qxcx630zEz2l0VPTC6XmEhkG5ipJKfj1dubE7oRhZVG0BwtPVDfZlF_o1eT8ItwLmx17MXFiOeQ=" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p align="justify"><strong>Note Regarding Forward-Looking Statements</strong></p>  <p align="justify">This news release may contain forward-looking statements relating to, among other things, the success of the fundraising initiative, the anticipated benefits and timelines discussed above, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2026, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as any subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p align="justify"><strong>Corporate Contact</strong></p>  <p align="justify">CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=K2in_J9d8VXVCtWKsXNu0evS8pzBBodjwTDilOmfQPrSVYMNBrq6CGeMIAsOp1Re59z8Kvo5efMdVyCoyOa39A==" rel="nofollow" target="_blank">ir@cytodyn.com</a></p>  <p align="justify"><strong>Media Contacts</strong></p>  <p align="justify">David Schull or Ignacio Guerrero-Ros, Ph.D.&nbsp;&nbsp;<br>Russo Partners, LLC&nbsp;<br><a href="https://www.globenewswire.com/Tracker?data=gWmXb28B76E4TLLlBqLzkejdKAC_WM4MIbdP_tTocnwPpcQosGnGrbmCxDbM2braqdBRrsxGeNCJOsswtl2b8RYTC-qwAU2tGL_N04H3t7u0XqXemw3tJn-ReodagW0ODCmLF4ht1Td6zqlNCKNIqJ0Re2ve0UVN7bpGIu5FsbEltGk9L6oRvK-_fEy-AUnTxEGgX0kkwoLxzwx-gIbeVp3D7b9nKAXOL3Dt_625rBFJQaIk2Emq4KxCzSLmfbCiVGvhTLShKIHwi3qd6egspymqm6oaa9xMd-ti8p6g3rkZFFXcQF9kpKPlLI8IU1Ga" rel="nofollow" target="_blank"><u>CytoDyn@russopartnersllc.com</u></a>&nbsp;</p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
    <item>
      <title>CytoDyn Announces First Patient Dosed in Phase 2a Study in Collaboration with Weill Cornell Medicine Evaluating Leronlimab in Alzheimer’s Disease</title>
      <link>https://www.cytodyn.com/newsroom/press-releases/detail/666/cytodyn-announces-first-patient-dosed-in-phase-2a-study-in</link>
      <pubDate>Thu, 11 Jun 2026 08:30:00 -0400</pubDate>
      <guid isPermaLink="true">https://www.cytodyn.com/newsroom/press-releases/detail/666/cytodyn-announces-first-patient-dosed-in-phase-2a-study-in</guid>
<content:encoded><![CDATA[

<p align="center"><em>Phase 2a study will evaluate the safety and biological activity of leronlimab in patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer’s disease</em></p>  <p align="justify">VANCOUVER, Washington, June  11, 2026  (GLOBE NEWSWIRE) -- <strong>CytoDyn Inc. (OTCQB: CYDY)</strong>&nbsp;("CytoDyn" or the "Company"), a clinical-stage oncology company advancing leronlimab, a first-in-class humanized monoclonal antibody targeting the CCR5 receptor with therapeutic potential across multiple therapeutic indications, today announced that the first patient has been dosed in a Phase 2a clinical study evaluating leronlimab in patients with Alzheimer’s disease, in collaboration with Weill Cornell Medicine.</p>  <p align="justify">The study, known as <a href="https://www.globenewswire.com/Tracker?data=jl9PuGjRUvpvFOExLe_5MYkPqas_8g43VlWSJ6QeKdpaF_TcQZDzgv8VVN7_BbeCJvOSD3GZtZ7VHlu9iveWm_PEg2xeimEUFkZrpmnuoGCEbEZtL4BopqpRMe4LmK36" rel="nofollow" target="_blank">SALIENT-AD</a> (Safety Assessment of Leronlimab and Its Effect on Neuroinflammation Targets in Alzheimer’s Disease), is a Phase 2a, open-label, proof-of-concept study designed to evaluate the safety and biological activity of leronlimab in approximately 10 to 20 patients over the age of 50 with early-stage, biomarker-confirmed Alzheimer’s disease. Patients will receive weekly subcutaneous injections of leronlimab over a 12-week treatment period. The primary endpoint will assess changes in brain inflammation and microglial activation using advanced PET imaging techniques. Secondary endpoints include safety and tolerability, cognitive assessments, blood-based biomarkers of inflammation and neurodegeneration, and measures of blood-brain barrier integrity using MRI. The study will be led by Tracy Butler, MD, Associate Professor of Neurology in Radiology and Psychiatry and Medical Director of the Brain Health Imaging Institute at Weill Cornell Medicine.</p>  <p align="justify">“This study is designed to evaluate whether modulation of CCR5 can meaningfully impact neuroinflammatory processes that are increasingly recognized as central to Alzheimer’s disease,” said Dr. Butler. “We are leveraging advanced imaging and biomarker tools to better understand how targeting immune signaling pathways may influence disease biology.”</p>  <p align="justify">“While CytoDyn remains focused on developing leronlimab in oncology, and we are especially encouraged by the early readouts from our CLOVER Phase 2 study in patients with mCRC, the collaboration with Weill Cornell Medicine in the SALIENT-AD study represents an opportunity to explore potential patient benefit in an indication that represents a significant unmet need,” said Jacob Lalezari, M.D., chief executive officer, CytoDyn. </p>  <p align="justify">Alzheimer’s disease is a complex and multifactorial neurodegenerative condition characterized not only by amyloid-beta plaques and tau tangles, but also by chronic neuroinflammation, microglial activation, and disruption of the blood-brain barrier. Emerging research suggests that CCR5, a chemokine receptor expressed on immune cells, may play a central role in regulating these processes.</p>  <p align="justify">Preclinical and translational research suggests that CCR5 plays a role in synaptic plasticity, memory formation, and microglial signaling, and may influence processes such as autophagy, vascular health, and blood-brain barrier stability. By blocking CCR5, leronlimab may help reduce maladaptive immune signaling and support neuronal resilience.</p>  <p><strong>About CytoDyn</strong><br>CytoDyn is a clinical-stage oncology company dedicated to advancing leronlimab, a first-in-class humanized monoclonal antibody that targets the CCR5 receptor, a key regulator of immune function implicated in cancer, infectious diseases, and autoimmune disorders. Guided by a mission to improve patients’ quality of life through therapeutic innovation, CytoDyn is committed to integrity, responsibility, and service as it works to bring transformative treatments to patients worldwide.</p>  <p align="justify">For more information, please visit&nbsp;<a href="https://www.globenewswire.com/Tracker?data=l_3LV-Y2HOMhLcYP2am6ykCsdR513e9fa7tPZaUz5819tZBl48vXyyN5vSjR9dhqQz-nN9NozdwurPf16PbAhsO-2YGj8ufYDy2_iED0V43z9zbrmwnOE04QAK9vcXEHr8qciHAIo1_D0peVpV8r2vPAH0aPPDiuoOdq4xQh9UvVfC7A9_ml7AmbULmxpdMrJx0kaCiMuQQdonaa-WNCiVbpqC5jJPeTlbIw5EjvIbFG3emo9R8oVnCG_-iDahcF6ZvhTpgS00ZKV37nkSiUmg==" rel="nofollow" target="_blank">www.cytodyn.com</a>&nbsp;and follow us on&nbsp;<a href="https://www.globenewswire.com/Tracker?data=qIEnarYO7UgUiG0UaXYRdGZL8oPI2u0bnLp2BbN-3zJnbbJT02hTmYtu35CY7v3p_PwcRtGt-zj3y1Z6zrg4tL2L49xME9zYGJo1BuSFqTDioy0k_wsgG9jjI1aJlUFOWZ1jKk3lUs_VdaokMWm7PLGQCFfte5VLjv_gyfgkmGFxz78yuoGTmuBzRbFN6DEasGFkcSZai-TtfxRQrbLn76u0scuwM6JmTkFcKgRZPgI1YYZ088exCIeleEeTzxlU" rel="nofollow" target="_blank">LinkedIn</a>.</p>  <p><strong>Note Regarding Forward-Looking Statements</strong><br>This news release may contain forward-looking statements relating to, among other things, the mechanism of action of leronlimab, clinical trial results, product development, market position, future operating and financial performance, and business strategy. The reader is cautioned not to rely on these statements, which are based on current expectations of future events. For important information about these statements and our Company, including the risks, uncertainties and other factors that could cause actual results to vary materially from the assumptions, expectations and projections expressed in any forward-looking statements, the reader should review our Annual Report on Form 10-K for the fiscal year ended May 31, 2025, including the section captioned “Forward-Looking Statements” and in Item 1A, as well as subsequent reports filed with the Securities and Exchange Commission. CytoDyn Inc. does not undertake to update any forward-looking statement as a result of new information or future events or developments except as required by applicable law.</p>  <p><strong>Corporate Contact</strong><br>CytoDyn Inc.<br><a href="https://www.globenewswire.com/Tracker?data=H3hVMoCnVSb5wYSxY8sAKVzF_NesoouaRx_ge52G6ZDAvMnwLz_ohFTd0122t091j9fIo2GbPvMYijXgbxIUBTk8GwuOhziDDvOS-xfQ554FbPkkNdrQ9yweoM0YXEO3ZL6XnVMg6LiVQvTY0SlcToxSV3l_nE9qJSU0kk3itt8a4HwbybJeiMxZB09sqmzowtK38MRZjrU5TaqXPq4-qVaPfslJbPrdG8L8GNkof58=" rel="nofollow" target="_blank">ir@cytodyn.com</a></p>  <p><strong>Media Contacts</strong><br>David Schull or Ignacio Guerrero-Ros, Ph.D.<br>Russo Partners, LLC<br><a href="https://www.globenewswire.com/Tracker?data=rsw192d0Lse0APkOF6NgEjk4wgIVkeV7A2dfsQD8-3RiLDLnkrQIvoORCTGmOBwYTl1gO-C5bTyixWCtrQozI65LMEWmZeIpgqDkKd_IjSk6gErO8-4dIOFobonv3VgaWKLHlQUDn6DjB1lvbfXXcD_ONEOeQa02sPIxr-CCkPzkZRtIxAyaEbajxnWO85KF_vnPlZ9DlE0LI2oWmbAobN3vga-kB2bBEfVqeutIyuiqGdh0LhARPjeGRpkgudpjZTej7EbkZn628PWjWMFVL8WGJNT3xalC_3LuvBHdlztBg6VCuCO9Wdi37ipwS9Q3" rel="nofollow" target="_blank">CytoDyn@russopartnersllc.com</a></p>  <br><p><a href="https://www.globenewswire.com/NewsRoom/AttachmentNg/3b426b4d-6299-4c23-9f95-058174a5b7be"><img src="https://ml.globenewswire.com/media/3b426b4d-6299-4c23-9f95-058174a5b7be/small/new-logo-png.png" border="0" width="150" height="34" alt="Primary Logo"></a></p>
Source: CytoDyn Inc.

]]></content:encoded>    </item>
  </channel></rss>